GlassScriptPhysician profile
Prince M Anand
NPI 1437310968
$331,206.84
in general payments reported to CMS, 2019-2025
16 companies · $143K in 2025
The $143K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $8,986 · 2021: $18K · 2022: $37K · 2023: $44K · 2024: $81K · 2025: $143K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $121K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $47K · Travel and Lodging: $47K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Consulting Fee: $20K · Food and Beverage: $6,233 · Education: $83.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $120,781.25 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $47,036.00 |
| Travel and Lodging | $47,006.10 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,344.00 |
| Consulting Fee | $20,038.50 |
| Food and Beverage | $6,232.58 |
| Education | $83.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $157,010.94 | 2022-2025 | Tarpeyo |
| Veloxis Pharmaceuticals, INC. | $68,190.33 | 2020-2023 | Envarsus |
| Apellis Pharmaceuticals, INC. | $62,164.15 | 2025 | Empaveli |
| Sanofi-Aventis U.S. LLC | $38,132.64 | 2024-2025 | |
| Novo Nordisk INC | $4,440.48 | 2023-2025 | Rivfloza |
| Novartis Pharmaceuticals Corporation | $331.50 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $303.91 | 2024-2025 | Ultomiris, Soliris |
| Mallinckrodt Hospital Products INC. | $188.87 | 2022-2025 | Acthar |
| Genzyme Corporation | $142.89 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.19 | 2022-2023 | Livtencity |
| Otsuka America Pharmaceutical, INC. | $61.20 | 2019 | |
| Travere Therapeutics, INC. | $50.37 | 2025 | |
| Exact Sciences Corporation | $30.43 | 2025 | The Cologuard Plus Collection Kit |
| Ethicon US, LLC | $21.42 | 2024 | Vistaseal |
| Eurofins Viracor, LLC | $20.30 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.22 | 2025 | Prevymis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prince Anand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.